Tyrosine-protein kinase JAK2 — Drug Target

All drugs that target Tyrosine-protein kinase JAK2 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Janus Kinase Inhibitor [EPC] · Kinase Inhibitor [EPC]

Marketed (3)

• Olumiant · Eli Lilly · Janus Kinase Inhibitor [EPC] · Immunology
• Corectim · Japan Tobacco · Janus Kinase Inhibitor [EPC] · Immunology
  Delgocitinib works by blocking the JAK2 enzyme, which plays a key role in the immune system's inflammatory response.
• Vonjo · Sobi · Kinase Inhibitor [EPC] · Oncology
  Vonjo works by blocking the activity of the JAK2 enzyme, which is overactive in myelofibrosis patients.